Goldman Sachs has adjusted its recommendation on Beiersdorf (ETR:BEIG), moving the stock from Buy to Neutral in a note dated Friday. The change follows the company’s FY25 update and reflects a reassessment of sales momentum, profitability outlook and the timing of benefits from a strategic reset of its NIVEA franchise.
Price target and current market price - Goldman Sachs left a 12-month price target of €90 on the shares, compared with a prevailing market price of €75.22 at the time of the note.
Sales concentration and regional exposure - The firm underlined Beiersdorf’s heavy dependence on the NIVEA brand, which represents 68% of the company’s Consumer sales. Within that Consumer segment, Europe accounts for 44% of sales, increasing the company’s sensitivity to regional performance.
Near-term sales outlook - Goldman Sachs set out a conservative organic growth profile for the group: 0.5% in FY26, followed by 3% in FY27 and 3.5% in FY28. For Q1 2026 specifically, the bank expects total organic sales to drop by 4.2%. It forecasts declines across divisions - Consumer down 4.0% and tesa down 4.7% - driven by an anticipated 7% fall in NIVEA and a 20% decline at La Prairie. These decreases are forecast to be partially offset by an 8% increase in Derma.
Brand recalibration and timing uncertainty - Beiersdorf began recalibrating NIVEA in the second half of 2025. The company’s efforts are focused on Face Care, Body Care and Deodorants and include changes to local execution. Goldman Sachs noted that uncertainty remains around when investors should expect to see a meaningful step-up in growth from these actions.
Margin outlook and cost pressures - The brokerage expects EBIT margin deterioration, forecasting a 40 basis point decline in FY26 to 13.6% and projecting no margin improvement in FY27. The note attributes margin pressure to raw material cost inflation, foreign exchange headwinds and limited operating leverage, in addition to the near-term earnings impact of the NIVEA recalibration and geographic expansion initiatives.
Revised earnings and revenue forecasts - Goldman Sachs reduced EPS estimates by 2.7% for FY26, 3.3% for FY27 and 3.4% for FY28. It also lowered its FY26 revenue forecast to €9.86 billion, down from a prior estimate of €10.0 billion.
Division dynamics - While Derma continues to expand, Goldman Sachs emphasized that it comprises 18% of Consumer sales and is insufficient, on its own, to offset the expected weakness in NIVEA.
Implications for markets - The note centers on company-specific issues - brand concentration, margin compression and execution timing - that bear most directly on Beiersdorf’s equity. Consumer staples and personal care suppliers with similar brand concentrations or geographic exposures could face analogous scrutiny from investors and analysts.